Bibliografía del artículo
1. Swedberg K, Eneroth P, Kjekshus J, Wilhelmensen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82:1730-36.
2. Ruilope LM, Barrios V, Volpe M. Renal implications of the renin-angiotensin-aldosterone system blockade in heart failure. J Hypertens 2000; 18:1545-61.
3. Barrios V, Ortega J. ACE inhibitors in the treatment of heart failure. Heart Failure 1999; Train Lett 7:2-5.
4. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systemic overview of data from individual patients. Lancet 2000; 35:1575-81.
5. McMurray J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, Hobbs FD, et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: Putting guidelines into practice. Eur J Heart Fail 2005; 7:710-21.
6. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2005; 112:1825-52.
7. Brown B, Hall AS. Renin-angiotensin system modulation: the weight of evidence. Am J Hypertens 2005; 18:127S-133S.
8. Mair FS, Crowleu TS, Brundred PE. Prevalence, aetiology and management of heart failure in general practice. Br J Gen Pract 1996; 46:77-79.
9. Houghton A, Cowley A. Why are angiotensin converting enzyme inhibitors underutilized in the treatment of heart failure by general practitioners? Int J Cardiol 1997; 59:7-10.
10. Lenzen MJ, Scholte OP, Reimer WJ, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 2004; 25:1214-20.
11. Boyles PJ, Peterson GM, Bleasel MD, Vial JH. Undertreatment of congestive heart failure in an Australian setting. J Clin Pharm Ther 2004; 29:15-22.
12. Masoudi FA, Rathore SS, Wang Y, et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 2004; 110:724-31.
13. Muntwyler J, Cohen-Solal A, Freemantle N, et al. Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe. Eur J Heart Fail 2004; 6:663-68.
14. Murphy NF, Simpson CR, McAlister FA, et al. National survey of the prevalence, incidence, primary care burden, and treatment of heart failure in Scotland. Heart 2004; 90:1129-36.
15. Roman-Sanchez P, Conthe P, Garcia-Alegria J, et al. Factors influencing medical treatment of heart failure patients in Spanish internal medicine departments: a national survey. QJM 2005; 98:127-38.
16. McMurray JJ. Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors? Eur Heart J 1998; 19(Suppl L):L15-21.
17. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160:685-93.
18. Benedict CR, Francis GS, Shelton B et al for the SOLVD investigators. Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. Am J Cardiol 1995; 75:1151-57.
19. Juillerat L, Nussberger J, Menard J, Mooser V, Christen Y, Waeber B, Graft P, Brunner H. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990; 16:564-72.
20. Roig E, Pérez-Villa F, Morales M, Jiménez W, Orús J, Heras M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000; 21:53-57.
21. Ferrari R, Guardigli G. Cicchitelli G, Valgimigli M, Soukhomovskaia O, Ceconi C. Cardioprotection with ACE inhibitors non-angiotensin II-related mechamisms. Eur Heart J Supplements 2000; 2(Suppl I):I22-28.
22. Barrios V, Campuzano R. Utilidad de los ARA II en la insuficiencia cardíaca. Rev Clin Esp 2003; 203:28-32.
23. Lombera F, Barrios V, Soria F, Placer L, Cruz JM, Tomás L, et al. Guías de práctica clínica de la Sociedad Española de Cardiología en hipertensión arterial. Rev Esp Cardiol 2000; 53:66-90.
24. Remme WJ. Heart failure management: why evidence does not influence clinical practice. Eur Heart J Supplements 2000; 2(Suppl I) I15-21.
25. Barrios V, Tamargo J, Llisterri JL, Palazuelos V, Lozano JV, Prieto L, et al. Encuesta sobre la situación de la insuficiencia cardíaca en Atención Primaria. Rev Esp Cardiol 2000; 53(Suppl 2):60.
26. Meffert S, Stoll M, Steckelings UM, Bottari SP, Unger T. The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol Cell Endocrinol 1996; 122:59-67.
27. Ruilope LM, Barrios V. Pharmacologic treatment in hypertensive heart disease. En: Crawford MH, DiMarco JP, editores. Cardiology. London: Mosby; 2001. p.8.1-8.8
28. Gottlieb S, Dickstein K, Fleck E, Kustis J, Levine TB, LeJemtel T, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 88:1602-09.
29. Dickstein K, Chang P, Willenheimer R, Haunso S, Remes J, Hall C, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise perfomance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995; 26:438-45.
30. Riegger GAJ, Bouzo H, Petr P, Münz J, Spacek R, Pethig H, et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation 1999; 100:2224-30.
31. Pitt B, Segal R, Martínez FA, Meurers G, Cowley AJ, Thomas I, et al, on behalf of ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349:747-52.
32. Pitt B, Poole-Wilson PA, Segal R, Martínez FA, Dickstein K, Camm AJ, et al, on behalf of ELITE Study Investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355:1582-87.
33. Konstam MA, Neaton JD, Poole-Wilson PA, Pitt B, Segal R, Sharma D, et al. Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). Am Heart J 2005; 150:123-31.
34. Dickstein K, Kjekshus J and the OPTIMAAL steering committee for the optimal study group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360:752-60.
35. Azizi M, Linhart A, Alexander J, Goldberg A, Menten J, Sweet J, Menard J. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. J Hypertens 2000; 342:1139-47.
36. Cohn JN, Tognoni G for the Valsartan Heart Failure Trial investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-75.
37. Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN on behalf of the Val-HeFT Investigators. Effect of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002; 40:1414-21.
38. Wong M, Staszewsky L, Latini R, Barlera S, Glazer R, Aknay N, et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. J Am Coll Cardiol 2004; 43:2022-27.
39. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2004; 349:1893-1906.
40. Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G, et al, for the CHARM-Programme Investigators. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM): rationale and design. J Card Fail 1999; 5:276-82.
41. McMurray JJ, Ostergren J, Swedberg K, et al, CHARM investigators and committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767-71.
42. Granger CB, McMurray JJ, Yusuf S, et al, CHARM investigators and committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362:772-76.
43. Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, et al., for the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction. Results from the CHARM low-left ventricular ejection fraction trials. Circulation 2004; 110:2618-26.
44. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362:777-81.
45. O'Meara E, Solomon S, McMurray J, et al. Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: assessment of Reduction in Mortality and Morbidity (CHARM) programme. Eur Heart J 2004; 25:1920-26.
46. Barrios V. Insuficiencia cardíaca con función ventricular deprimida. Estudio CHARM. Rev Esp Cardiol Supl 2004; 4:12B-20B.
47. Yusuf S, Ostergren JB, Gerstein HC, Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005; 112:48-53.
48. Swedberg K, Pfeffer M, Cohen-Solal A, Ducharme A, Granger C, Michelson E et al. Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan: Results from CHARM (abstract). JACC 2004; 43:222A.
49. The Study of Left Ventricular Dysfunction (SOLVD) Investigators. Effects of Enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
50. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353:2001-07.
51. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999; 341:709-17.